Adia Med Fully Repays Related-Party Credit Facility, Strengthening Its Financial Position
Remaining obligations consist of ordinary operating leases, with no new credit facility currently in place.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Adia Med (ADIA) fully repaid and discharged its unsecured revolving credit facility with Chief Executive Officer Larry Powalisz on October 9, 2026.
Total repayment was $934,970.94, covering outstanding principal and accrued interest. The facility had a $1,000,000 commitment and carried 6% annual interest. Remaining obligations consist of the Winter Park clinic lease and one medical equipment lease.
How this balance works
Rhea-AI gives every point it takes from this document a weight. Minor counts 1, Moderate 3 and Major 9, so one Major point outweighs several Minor ones. The bar adds up the weights on each side, and when neither side holds more than 65% of the total the balance reads Mixed.
It reads the document as published, with the same rules for every company, and it does not look at what the market expected or at how the stock traded, so a point can be objectively good on a day the stock falls.
Rhea-AI Sentiment measures something else, the tone of the wording.
Positive
- Moderate point$934,970.94 repayment fully discharged the CEO-provided credit facility, including outstanding principal and accrued interest. 6.7% of market cap
- Minor point6% annual-interest facility retired; remaining obligations consist of the clinic lease and one medical equipment lease.
Negative
- Minor point$74,658.94 in accrued interest was included in the final payment.
AI-generated analysis. How Rhea-AI works. Not financial advice.
Full repayment eliminates the Company's unsecured revolving credit facility and simplifies its remaining obligations
Winter Park, Florida--(Newsfile Corp. - October 13, 2026) - Adia Med, Inc. (OTCQB: ADIA) (the "Company") today announced the full repayment and discharge of its unsecured revolving line of credit with Larry Powalisz, the Company's Chief Executive Officer.
Adia Med Fully Repays Related-Party Credit Facility, Strengthening Its Financial Position
To view an enhanced version of this graphic, please visit:
https://images.newsfilecorp.com/files/10520/318700_adiamed.jpg
Financial Highlights
$934,970.94 repaid in total, including all outstanding principal and accrued interest.$500,000 paid on October 7, 2026, followed by a final payment of$434,970.94 on October 9, 2026.- The final payment included
$74,658.94 of accrued interest. - The facility, established on June 30, 2024, had been increased to a
$1,000,000 commitment and carried interest at6% per annum. - Mr. Powalisz acknowledged that the facility was fully satisfied and discharged as of October 9, 2026.
A Simplified Financial Profile
With the repayment complete, the Company's remaining obligations consist of ordinary operating leases: the lease for its clinic in Winter Park Florida and one medical equipment lease.
"We are pleased to have retired this facility and simplified our balance sheet," said Larry Powalisz, Chief Executive Officer. "The Company met its obligations in full and on a timely basis."
Future Financial Flexibility
If the Board of Directors determines that additional capital is needed in the future, Mr. Powalisz has indicated that he would be willing to consider providing a new line of credit. No such facility is currently in place.
Additional details are included in the Company's Current Report on Form 8-K filed with the Securities and Exchange Commission.
For questions, inquiries, or additional information, please contact Larry Powalisz at ceo@adiamed.com or by phone at 321-231-2843.
About Adia Med Inc.
Adia Med Inc. (OTCQB: ADIA), headquartered in Winter Park, Florida, is a regenerative medicine company built around active, IRB-approved stem cell therapy studies. Through its Adia Med clinics, the company delivers stem cell treatments alongside complementary services like platelet-rich plasma (PRP), therapeutic plasma exchange (TPE), and autologous hematopoietic stem cell transplantation (aHSCT), supported by multiple Institutional Review Board (IRB)-approved clinical studies, The current studies are targeting autism spectrum disorder, chronic kidney disease, and lower back pain, with more planned for 2026. Its Adia Labs division manufactures regenerative products (AdiaVita, AdiaLink) that supply this clinical work.
Adia Labs generates revenue by manufacturing and selling regenerative products (AdiaVita and AdiaLink) to Adia Med clinics and external providers. Adia Med clinics generate revenue through patient treatments (stem cell therapies, PRP, TPE, and aHSCT). Additional revenue comes from the company's
Website: www.adiamed.com
Website: www.adialabs.com
Website: www.cementfactory.co
Twitter (X): @adia_med
Instagram: @adia_med
Facebook: @adia_med
Safe Harbor: This Press Release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. These forward-looking statements are based on the current plans and expectations of management and are subject to a few uncertainties and risks that could significantly affect the company's current plans and expectations, as well as future results of operations and financial condition. A more extensive listing of risks and factors that may affect the company's business prospects and cause actual results to differ materially from those described in the forward-looking statements can be found in the reports and other documents filed by the company with the Securities and Exchange Commission and OTC Markets, Inc. OTC Disclosure and News Service. The company undertakes no obligation to publicly update or revise any forward-looking statements, because of new information, future events or otherwise.
To view the source version of this press release, please visit https://www.newsfilecorp.com/release/318700
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
Could Adia Med obtain another credit line from its CEO?
Larry Powalisz indicated willingness to consider providing a new line of credit if the board determines additional capital is needed. No such facility is currently in place.